# Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043)

> **NCT04193202** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 419 (actual)

## Conditions studied

- Chronic Cough

## Interventions

- **DRUG:** Gefapixant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04193202
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-21
- **Primary completion:** 2021-10-19
- **Final completion:** 2021-11-03
- **Target enrollment:** 419 (ACTUAL)
- **Last updated:** 2023-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04193202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04193202, "Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04193202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*